Assenagon Asset Management S.A. Has $6.77 Million Position in Bruker Co. (NASDAQ:BRKR)

Assenagon Asset Management S.A. increased its holdings in Bruker Co. (NASDAQ:BRKR) by 11.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 115,508 shares of the medical research company’s stock after purchasing an additional 11,860 shares during the period. Assenagon Asset Management S.A. owned approximately 0.08% of Bruker worth $6,771,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. True Wealth Design LLC increased its holdings in shares of Bruker by 4,636.4% during the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock worth $36,000 after buying an additional 510 shares in the last quarter. Eagle Bay Advisors LLC increased its holdings in Bruker by 2,324.1% during the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 674 shares in the last quarter. UMB Bank n.a. raised its position in Bruker by 115.3% in the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 354 shares during the last quarter. Gordian Capital Singapore Pte Ltd acquired a new position in Bruker in the second quarter worth $52,000. Finally, GAMMA Investing LLC grew its holdings in shares of Bruker by 81.0% during the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock worth $60,000 after purchasing an additional 388 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on BRKR shares. Bank of America upped their price target on shares of Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. The Goldman Sachs Group upgraded shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price on the stock in a research report on Thursday, December 5th. Citigroup lowered their price target on shares of Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. TD Cowen reduced their price objective on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a report on Wednesday, November 6th. Finally, Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $74.45.

Insider Transactions at Bruker

In related news, CEO Frank H. Laukien bought 100,000 shares of Bruker stock in a transaction that occurred on Monday, November 18th. The stock was purchased at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the purchase, the chief executive officer now owns 38,439,563 shares in the company, valued at approximately $1,927,359,688.82. This trade represents a 0.26 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 28.30% of the stock is currently owned by insiders.

Bruker Price Performance

Shares of BRKR opened at $56.88 on Monday. The stock has a market cap of $8.62 billion, a P/E ratio of 27.35, a price-to-earnings-growth ratio of 3.55 and a beta of 1.17. Bruker Co. has a 1 year low of $48.07 and a 1 year high of $94.86. The stock’s 50-day moving average price is $57.79 and its two-hundred day moving average price is $61.66. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24.

Bruker (NASDAQ:BRKR) last issued its earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.01). The firm had revenue of $864.40 million during the quarter, compared to the consensus estimate of $866.46 million. Bruker had a net margin of 9.41% and a return on equity of 21.52%. The firm’s revenue for the quarter was up 16.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.74 EPS. On average, equities analysts predict that Bruker Co. will post 2.39 earnings per share for the current year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Monday, December 2nd were issued a $0.05 dividend. The ex-dividend date was Monday, December 2nd. This represents a $0.20 annualized dividend and a dividend yield of 0.35%. Bruker’s dividend payout ratio (DPR) is currently 9.62%.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.